Latest Commercialization News

Cambium Bio has locked in a A$2.4 million strategic investment from Zheng Yang Biomedical Technology, reinforcing its push into pivotal Phase 3 trials for its dry eye disease treatment.

Golden State Mining Limited has appointed a new board and managing director, completed a $1.5 million capital raising, and is advancing exploration with a disciplined approach focused on its Western Australian gold projects.

Pioneer Minerals has validated primary tungsten mineralisation at its Springfield Prospect in Idaho, revealing high-grade scheelite and gold assays that underpin a promising multi-phase mineral system. The project’s proximity to established processing infrastructure offers strategic advantages for future development.

Pacific Edge reports a 13.4% decline in test volumes for Q3 2026 but gains strategic momentum with a key Medicare advisory meeting and clinical endorsements poised to influence reimbursement policy.

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.

Trek Metals reports exceptional high-grade manganese rock chip assays up to 60.1% Mn at its Kuro Prospect, extending mineralisation over 750 metres and aligning with strong gravity anomalies. Drill preparations and heritage assessments are underway to unlock the discovery’s full potential.

4DMedical Limited has raised AU$150 million to accelerate the commercial rollout of its FDA-cleared CT, VQ lung imaging technology in the US, leveraging a strategic partnership with Philips. This funding aims to expand adoption across major medical centres and government healthcare programs.

SportsHero Limited has reported its highest quarterly cash receipts since listing, driven by a milestone payment from its Philippines launch and rapid subscriber growth for its HeroPlay platform in Indonesia.

Tivan Limited has completed its acquisition of the Molyhil Tungsten-Molybdenum Project in the Northern Territory and is fast-tracking development with a drilling program planned for March 2026 to explore resource expansion.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.

Alligator Energy has completed its Samphire pilot plant on time and under budget, setting the stage for a critical Field Recovery Trial in early 2026. The company also divested non-core Northern Territory assets to sharpen its focus and strengthen liquidity for its South Australian uranium projects.

Amaero Ltd has reported a remarkable 366% increase in revenue for the first half of FY2026, alongside key capital investments and formal validation from the US Navy, signalling a strong move towards scaled commercial production.